Zoetis Holds Investor Day and Presents Strategy to Shape Animal Health for the Next Decade
Zoetis Inc. (NYSE:ZTS) is hosting an investor day at 9:00 a.m.
ET today at the New York Stock Exchange, where the company will
dive into its compelling growth ambitions, its innovative and
robust R&D pipeline and its financial roadmap to continue
delivering shareholder value, as it Shapes
Animal Health for the Next Decade.
During today’s presentations, Chief Executive Officer Kristin
Peck, Chief Financial Officer Wetteny Joseph, President of Research
& Development Robert Polzer, Ph.D., and other members of the
Zoetis executive team will outline the company’s plans to deliver
on its ambitions by:
- Building on its leadership in Animal Health to shape and expand
the future of animal care.
- Delivering growth in a dynamic and resilient industry by
innovating and growing faster than the market.
- Driving its next phase of game-changing franchises through
internal R&D and business development.
- Investing in capabilities and innovation that differentiate
- Continuing to create value for shareholders through revenue
growth, strategic investments, margin expansion and capital
Franchises Fueling Future Growth Zoetis sees long-term
sustainable growth driven by new products and lifecycle innovations
for companion animals and livestock. The executive team will
discuss its strategy for expanding its current billion-dollar
franchises in dermatology and pet parasiticides, and new
expectations for its osteoarthritis pain franchise to reach more
than $1 billion in peak sales. Zoetis will also provide an update
on its R&D pipeline and future growth opportunities in new
therapies for renal disease, cardiology and oncology, as well as
its livestock and diagnostics portfolios.
“Our growth and value creation is rooted in the right strategy,
a diverse portfolio, our leadership in innovation, and global
capabilities that allow us to capitalize on the opportunities we
see in an attractive Animal Health market,” said Kristin Peck,
Chief Executive Officer of Zoetis. “We pride ourselves on shaping
animal health and creating new markets based on game-changing
innovations. Based on our track record and talented colleagues, we
are confident in our ability to broaden our existing billion-dollar
franchises, while innovating and building new ones through
continued investments in R&D, supply chain and commercial
excellence,” said Peck.
New Ambitions for Value Creation Zoetis will also
introduce new ambitions for the four tenets of its long-standing
value proposition over the next 3-5 years, including:
- Growing annual revenue mid-to-high single digits,1 driven by
- Driving ROIC (Return On Invested Capital) accretion1 by
focusing on critical investment priorities.
- Enabling margin improvement1 through revenue growth in more
profitable product categories and greater leverage of its global
- And maintaining balance between investments and return of
capital with a disciplined capital allocation strategy.
“Our ability to identify and invest in the most promising
product categories have enabled us to grow faster than the market
while delivering compelling value to our shareholders for the past
decade. Zoetis has the right fundamentals and promising pipeline
opportunities to build on this track record and continue to grow
revenue at an attractive pace over the medium to long term, while
driving margin expansion,” said Wetteny Joseph, Chief Financial
Officer of Zoetis.
Webcast and Materials A live webcast of the investor day
presentations, along with supporting materials, can be accessed by
the general public today starting at 9:00 a.m. ET on Zoetis’
Investor Relations website. The event will conclude at 12:30 p.m.
ET. A replay of the live webcast will be archived and made
available after the event.
About Zoetis As the world’s leading animal health
company, Zoetis is driven by a singular purpose: to nurture our
world and humankind by advancing care for animals. After innovating
ways to predict, prevent, detect, and treat animal illness for more
than 70 years, Zoetis continues to stand by those raising and
caring for animals worldwide – from veterinarians and pet owners to
livestock farmers and ranchers. The company’s leading portfolio and
pipeline of medicines, vaccines, diagnostics and technologies make
a difference in over 100 countries. A Fortune 500 company, Zoetis
generated revenue of $8.1 billion in 2022 with approximately 13,800
employees. For more information, visit www.zoetis.com.
Forward-Looking Statements: This press release contains
forward-looking statements, which reflect the current views of
Zoetis with respect to: business plans or prospects, future
operating or financial performance and future guidance; future
operating models; future research and development growth
opportunities; future use of cash, dividend payments and share
repurchases; and other future events. These statements are not
guarantees of future performance or actions. Forward-looking
statements are subject to risks and uncertainties. If one or more
of these risks or uncertainties materialize, or if management's
underlying assumptions prove to be incorrect, actual results may
differ materially from those contemplated by a forward-looking
statement. Forward-looking statements speak only as of the date on
which they are made. Zoetis expressly disclaims any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events or otherwise. A further list and
description of risks, uncertainties and other matters can be found
in our most recent Annual Report on Form 10-K, including in the
sections thereof captioned “Forward-Looking Statements and Factors
That May Affect Future Results” and “Item 1A. Risk Factors,” in our
Quarterly Reports on Form 10-Q and in our Current Reports on Form
8-K. These filings and subsequent filings are available online at
www.sec.gov , www.zoetis.com , or on request from Zoetis.
ZTS-COR ZTS-FIN ZTS-IR
1 Targeted average over the forecast period
version on businesswire.com: https://www.businesswire.com/news/home/20230524005910/en/
Media: Bill Price 1-973-443-2742
Kristen Seely 1-973-443-2777 (o) email@example.com
Investor: Steve Frank
1-973-822-7141 (o) firstname.lastname@example.org
Nick Soonthornchai 1-973-443-2792 (o)
Historical Stock Chart
From Aug 2023 to Sep 2023
Historical Stock Chart
From Sep 2022 to Sep 2023